Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.8 USD | -0.22% | -11.60% | +28.97% |
May. 20 | Immunome Completes Purchase of Antibodies From Atreca | MT |
May. 17 | Immunome Appoints Max Rosett as CFO | MT |
Financials (USD)
Sales 2024 * | 10.04M | Sales 2025 * | 844K | Capitalization | 827M |
---|---|---|---|---|---|
Net income 2024 * | -193M | Net income 2025 * | -170M | EV / Sales 2024 * | 82.4 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 980 x |
P/E ratio 2024 * |
-3.88
x | P/E ratio 2025 * |
-5.08
x | Employees | 55 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 83.09% |
1 day | -0.22% | ||
1 week | -11.60% | ||
Current month | -1.85% | ||
1 month | -10.85% | ||
3 months | -40.00% | ||
6 months | +77.15% | ||
Current year | +28.97% |
Managers | Title | Age | Since |
---|---|---|---|
Clay Siegall
CEO | Chief Executive Officer | 63 | 23-10-01 |
Max Rosett
DFI | Director of Finance/CFO | 34 | 23-10-01 |
Bob Lechleider
CTO | Chief Tech/Sci/R&D Officer | 63 | 23-10-18 |
Members of the board | Title | Age | Since |
---|---|---|---|
Carol Schafer
BRD | Director/Board Member | 60 | Jan. 01 |
Director/Board Member | 70 | Nov. 06 | |
Clay Siegall
CEO | Chief Executive Officer | 63 | 23-10-01 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-20 | 13.8 | -0.22% | 1,342,376 |
24-05-17 | 13.83 | -3.96% | 699,021 |
24-05-16 | 14.4 | -2.70% | 811,105 |
24-05-15 | 14.8 | +0.54% | 935,341 |
24-05-14 | 14.72 | -5.70% | 1,131,615 |
Delayed Quote Nasdaq, May 20, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+28.97% | 827M | |
+9.58% | 115B | |
+12.41% | 107B | |
-2.59% | 21.6B | |
-12.38% | 22.31B | |
-5.29% | 19.19B | |
-3.35% | 18.23B | |
-38.57% | 17.62B | |
+7.51% | 14.26B | |
+35.67% | 12.37B |
- Stock Market
- Equities
- IMNM Stock